Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer by Corona SP, Generali D

Get full text

Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. by Patel, N, Li, J, Generali, D, Poulsom, R, Cranston, D, Harris, A

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLIC... by Foroni, C, Fox, S, Berruti, A, Dogliotti, L, Bottini, A, Harris, A, Generali, D

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. by Milani, M, Rzymski, T, Mellor, H, Pike, L, Bottini, A, Generali, D, Harris, A

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostat... by Bonetta A, Roviello G, Generali D, Zanotti L, Cappelletti MR, Pacifico C, Di Pierro F

Get full text

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients by Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Bonardi, S, Dogliotti, L, Harris, A, Bottini, A

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients by Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Allevi, G, Bonardi, S, Dogliotti, L, Bottini, A, Harris, A

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients. by Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Allevi, G, Bonardi, S, Dogliotti, L, Bottini, A, Harris, A

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. by Generali, D, Berruti, A, Foroni, C, Bazzola, L, Andreis, D, Allevi, G, Bersiga, A, Dogliotti, L, Fox, S, Harris, A, Bottini, A

The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. by Nikitenko, L, Leek, R, Henderson, S, Pillay, N, Turley, H, Generali, D, Gunningham, S, Morrin, H, Pellagatti, A, Rees, M, Harris, A, Fox, S

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer. by Fox, S, Generali, D, Berruti, A, Bates, G, Banham, A, Bonardi, S, Milani, M, Dionisio, R, Brizzi, M, Dogliotti, L, Bottini, A, Harris, A

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri... by Fox, S, Generali, D, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Mele, T, Dogliotti, L, Bottini, A, Harris, A

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. by Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients by Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to pri... by Fox, S, Generali, D, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Mele, T, Dogliotti, L, Bottini, A, Harris, A

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer by Generali, D, Fox, S, Berruti, A, Moore, J, Brizzi, M, Patel, N, Allevi, G, Bonardi, S, Aguggini, S, Bersiga, A, Campo, L, Dogliotti, L, Bottini, A, Harris, A

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. by Generali, D, Fox, S, Berruti, A, Moore, J, Brizzi, M, Patel, N, Allevi, G, Bonardi, S, Aguggini, S, Bersiga, A, Campo, L, Dogliotti, L, Bottini, A, Harris, A

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. by Generali, D, Buffa, F, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Papotti, M, Dogliotti, L, Bottini, A, Harris, A, Fox, S

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. by Generali, D, Bates, G, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Dogliotti, L, Banham, A, Harris, A, Bottini, A, Fox, S

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. by Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A